Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short-term Investments: 2016-2025

Historic Short-term Investments for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $57.5 million.

  • Tg Therapeutics' Short-term Investments fell 60.40% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 60.40%. This contributed to the annual value of $131.1 million for FY2024, which is 5.24% up from last year.
  • Tg Therapeutics' Short-term Investments amounted to $57.5 million in Q3 2025, which was down 53.15% from $122.7 million recorded in Q2 2025.
  • Tg Therapeutics' Short-term Investments' 5-year high stood at $145.2 million during Q3 2024, with a 5-year trough of $15.9 million in Q4 2021.
  • Moreover, its 3-year median value for Short-term Investments was $124.6 million (2023), whereas its average is $108.9 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first slumped by 69.46% in 2021, then surged by 273.99% in 2022.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Short-term Investments stood at $15.9 million in 2021, then surged by 273.99% to $59.4 million in 2022, then surged by 109.81% to $124.6 million in 2023, then climbed by 5.24% to $131.1 million in 2024, then slumped by 60.40% to $57.5 million in 2025.
  • Its Short-term Investments was $57.5 million in Q3 2025, compared to $122.7 million in Q2 2025 and $144.1 million in Q1 2025.